"These findings are encouraging for cancer patients undergoing chemotherapy," stated Denise Faltischek, chief strategy officer and head of international at Tilray Brands. "This study is a crucial step in improving patient care and quality of life. Our involvement in this study underscores our commitment to advancing medical research. The positive outcomes highlight the potential of cannabinoids for managing CINV.”
Read Also: Tilray, High Tide, Glass House: How Top Cannabis Companies Deal With Financial Pressures
Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter here. If you're serious about the business, you can't afford to miss out.
Study Highlights
The randomized, placebo-controlled trial tested the effectiveness of an oral cannabis extract in adults suffering from CINV despite standard anti-nausea treatments. Participants received capsules containing 2.5 mg of THC and 2.5 mg of CBD or a placebo, taken three times daily for six days.
The study found the cannabis extract significantly improved the rate of complete response from 8% with placebo to 24% with THC: CBD, with no use of additional medications. Benefits included reduced nausea and fewer daily vomits.
However, some side effects were noted, such as sedation (18% vs. 7%), dizziness (10% vs. 0%), and transient anxiety (4% vs. 1%). From 2016 to 2022, 147 participants were recruited for the study.
Tilray Launches ‘Men's Health on Tap' Podcast
Sfakianos and Kaplan noted that many men hesitate to discuss health concerns and may delay visiting the doctor, which can lead to more serious, undiagnosed conditions. In episode one of the podcast, they encourage men to discuss these topics openly and emphasize that regular check-ups and early intervention can help them lead healthier, longer lives.
“We are excited to launch ‘Men’s Health on Tap’ and break down stigmas around men’s health,” stated Sfakianos. “Our goal is to provide valuable information and resources that will help men take control of their health and wellness.”
Price Action
Tilray shares traded 1.30% higher at $1.56 per share during Thursday's pre-market session
Read Next:
Photo: Courtesy of Tinnakorn jorruang via Shutterstock
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.
